Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
This study has been completed.
Study NCT00031837 Information provided by National Cancer Institute (NCI)
First Received: March 8, 2002 Last Updated: August 19, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pancreatic Cancer
Thromboembolism
Additional conditions recognized in this trial
Pancreatic Neoplasms
More general conditions related to this trial
Cardiovascular Diseases
Digestive System Diseases
Digestive System Neoplasms
Embolism and Thrombosis
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms
Neoplasms by Site
Pancreatic Diseases
Thrombosis
Vascular Diseases
Interventions listed in this trial
dalteparin
gemcitabine hydrochloride
quality-of-life assessment
Additional drug interventions recognized in this trial
Gemcitabine
More general drug interventions related to this trial
Anti-Infective Agents
Anticoagulants
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Cardiovascular Agents
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
University of Rochester
National Cancer Institute (NCI)
Back to top of Main Content
